Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Marie Curie: Búsqueda de socios industriales en los sectores de farmacia, biotecnología o biología sintética para investigación amiloide

Resumen

Tipo:
Búsqueda de socios
Referencia:
RDUK20161215002
Publicado:
16/12/2016
Caducidad:
16/12/2017
Resumen:
Una universidad británica de Biología busca socios industriales con el fin de participar en un proyecto Marie Curie ITN con el fin de identificar el ciclo de vida de amiloides investigando la dinámica de formación y desensamblaje. El comportamiento dinámico de una variedad de proteínas que forman amiloides funcionales y patógenos será investigado desde un enfoque multidisciplinar, ofreciendo nuevas posibilidades en aplicaciones de biomedicina, biofilms, biosensores y bioelectrónica. La universidad busca socios en los sectores de farmacia, biotecnología o biología sintética. La fecha límite de la convocatoria es el 12 de enero de 2017.

Details

Tittle:
A Marie Curie: seeking industrial partners from a broad range of pharmaceutical, biotechnology or synthetic biology organisations interested in amyloid research
Summary:
A UK biological sciences university group is seeking industrial partners for a Marie Curie ITN investigating the life-cycle of amyloids. The partners can be from a range of sizes and backgrounds such as pharmaceutical, biotechnology or synthetic biology. Pharmaceutical companies would need an interest in amyloid diseases (Alzheimer´s etc). Biotechnology and synthetic biology companies should have an interest in developing novel biofilms, biosensors and/or bioelectronics from the amyloids.
Description:
Protein aggregates termed amyloids are the hallmarks of various neurodegenerative disorders. There is currently no cure available for any of these diseases. Recently, a drug that was seen as a major test of the leading theory behind Alzheimer´s disease has failed in a large trial of people with mild dementia. It becomes clear that we lack a fundamental understanding of the molecular mechanisms underlying these pathogenic conditions.

Amyloid fibrils are long, unbranched filaments that are composed of an ordered, repetitive arrangement of many copies of a peptide or protein, often referred to as the cross-ß-sheet motif. Numerous proteins form amyloid fibrils, some of which are functional and some of which are pathological. More than 40 proteins are known to form pathogenic amyloid fibrils and there are at least a dozen functional amyloid fibrils, with new members of both classes being discovered constantly.

The variety in amyloid assemblies may reflect their presence as a prominent fold early in the evolution of life. To date, functional amyloid has been identified in fungi, insects, bacteria, and humans. These findings reinforce the emerging concept of the amyloid cross-ß fold as a quaternary protein structure able to carry out a diversity of biological functions. This strongly suggests that amyloid assemblies must be subject to regulation, for example by reversing the amyloid assembly. In this respect, nature has given us some great examples in the form of functional amyloids. This network aims to identify the life cycle of amyloids by investigating the dynamics in amyloid formation and disassembly. The dynamic behavior of a variety of functional and pathogenic amyloid forming proteins and peptides will be investigated in a multidisciplinary approach, opening new avenues for biomedical, biofilm, biosensor and bioelectronic applications.

Hence, the partners can be from a range of backgrounds such as pharmaceutical, biotechnology or synthetic biology. Pharmaceutical companies would need an interest in amyloid diseases (Alzheimer´s etc). Biotechnology and synthetic biology companies should have an interest in developing novel biofilms, biosensors and/or bioelectronics from the amyloids.

The industrial partner in the project can be either ´partner´ or ´beneficiary´. Details regarding the funding available to each of these types of partner is given below. The network is seeking companies to host secondments, but not all companies need to.

A group of six partners have been identified already.

Programme: Marie Curie Innovative Training Network
Project duration: 4 years
Call deadline: 12th January 2017
EOI deadline: 12th January 2017

Partner sought

Partner Sought:
Type of partner - SME or larger industrial organisation Specific area of activity - pharmaceutical, biotechnology, biosensors, biofilms, bioelectronics or other area related to amyloid research Field of expertise - amyloids Tasks to be performed - describe your interest in the ITN and discuss participation
Type of Partnership Considered:
RDR

Client

Type and Size of Client:
University
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English

Dissemination

Programme-call

Evaluation Scheme:
H2020
Anticipated Project Budget:
not yet known
Coordinator Required:
No
Deadline for Call:
12/01/2017
Project Duration:
208